BioSpace News Archive

In honor of International Rare Disease Day, a young rare disease advocate with a leukodystrophy, Ellie McGinn, presented her doctors at Kennedy Krieger Institute’s Moser Center for Leukodystrophies with $450,000, bringing the total she and her family raised for research of the rare brain disease, Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation (LBSL), to $1.6 million in four years.

In a letter to the Food and Drug Administration, AACC is urging the agency to allow clinical laboratories to develop coronavirus tests without going through FDA review.

The U.S. Food and Drug Administration has approved an application for the first generic of Daraprim (pyrimethamine) tablets for the treatment of toxoplasmosis (an infection caused by the parasite Toxoplasma gondii) when used with a sulfonamide (a group of medicines used to treat bacterial infections).

Recognized by CMS for reducing disparities in colorectal cancer screening rates for vulnerable populations

MOUNTAIN VIEW, Calif., Feb. 28, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the fourth quarter and full year of 2019 after the close of trading on Thursday, March 12, 2020. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-303

Carisma Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at two conferences in March, 2020.

Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2019.

Today, the nationally recognized attorneys from Baron & Budd obtained an $11,850,000 settlement in a case against pharmaceutical marketing company, Sanofi-Aventis U.S., LLC. The company markets drugs, including Lemtrada, a treatment for patients with multiple sclerosis (MS).

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today reported financial results for its fourth quarter and full year ended December 31, 2019.

Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a global commercial manufacturer of high quality cannabinoid-based ingredients, formulations and products, is pleased to report its financial results for the third quarter of its fiscal year 2020, ended December 31, 2019. The financial statements and Management’s Discussion & Analysis are available under the Company’s profile at www.SEDAR.com.